Sugi Predict

Sugi Predict / Compounds / SCHEMBL383638

SCHEMBL383638

SCHEMBL383638

O=C1c2cc(Cl)c(Cl)cc2C(=O)N1c1ccc([C](c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA9 Q16790 9/20 0.71
▸ CA12 O43570 5/20 0.71
▸ CA1 P00915 4/20 0.71
▸ CA2 P00918 4/20 0.54
▸ SCN2A Q99250 1/20 0.54
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ GFER P55789 1/20 0.49
▸ ESR1 P03372 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ PPARA Q07869 1/20 0.47
▸ HPSE Q9Y251 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL522210 0.93 CA9 (0.75) CA9CA12CA1CA2SCN2A
SCHEMBL9633890 0.84 CA9 (0.66) CA9CA12CA1CA2SCN2A
SCHEMBL29710383 0.84 CA9 (0.66) CA9CA12CA1CA2SCN2A
SCHEMBL770162 0.78 APEX1 (0.52) CA9CA12CA1CA2MEN1
SCHEMBL5647824 0.78 ESR1 (0.70) CA9CA12CA1CA2MEN1
SCHEMBL513175 0.76 CA12 (0.69) CA9CA12CA1MEN1KMT2A
SCHEMBL15248669 0.75 CA9 (0.77) CA9CA12CA1CA2SCN2A
SCHEMBL5198978 0.74 ALDH1A1 (0.64) CA9CA12CA1CA2MEN1
SCHEMBL27475071 0.74 CA9 (0.62) CA9CA12CA1CA2MEN1
SCHEMBL2357830 0.73 CA9 (0.61) CA9CA12CA1CA2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121719-A2 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS Alios Biopharma, Inc. (US) 2009-11-25 — — EP claimed
WO-2009086192-A1 BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 — — WO claimed
WO-2009086201-A1 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 — — WO claimed
WO-2008095040-A2 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS ALIOS BIOPHARMA, INC. (US) 2008-08-07 — — WO claimed
WO-2000004062-A1 RECOVERY OF TRIARYLMETHYL HALIDE PROTECTING GROUPS CLEAVED DURING OLIGONUCLEOTIDE SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2000-01-27 — — WO claimed
EP-0648220-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA, Jyoti (SE) 1995-04-19 — — EP claimed
CN-117379452-A Substituted nucleosides, nucleotides and analogues thereof 艾丽奥斯生物制药有限公司 2024-01-12 — — CN disclosed
EP-3160475-B1 SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES TO TREAT FILOVIRIDAE INFECTIONS JANSSEN PHARMACEUTICALS INC (US) 2024-01-03 — — EP disclosed
EP-3013340-B9 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICALS INC (US) 2023-10-04 — — EP disclosed
EP-3013340-B1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN BIOPHARMA INC (US) 2023-06-07 — — EP disclosed
US-11590155-B2 Substituted nucleosides, nucleotides and analogs thereof JANSSEN PHARMACEUTICA NV (BE) 2023-02-28 — — US disclosed
US-11485753-B2 Substituted nucleosides, nucleotides and analogs thereof JANSSEN PHARMACEUTICA NV (BE) 2022-11-01 — — US disclosed
CN-113712989-A Substituted nucleosides, nucleotides and analogs thereof 艾丽奥斯生物制药有限公司 2021-11-30 — — CN disclosed
WO-2009086192-A1 BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 — — WO disclosed
WO-2009086201-A1 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 — — WO disclosed
US-20090176732-A1 PROTECTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA INC. (US) 2009-07-09 — — US disclosed
US-20080207554-A1 2-5A Analogs and their Methods of Use ALIOS BIOPHARMA, INC. (US) 2008-08-28 — — US disclosed
WO-2003059926-A2 METHODS AND COMPOSITIONS FOR AMINOACYL-tRNA SYNTHESIS UNIVERSITY OF MASSACHUSETTS (US) 2003-07-24 — — WO disclosed
WO-2000004062-A1 RECOVERY OF TRIARYLMETHYL HALIDE PROTECTING GROUPS CLEAVED DURING OLIGONUCLEOTIDE SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2000-01-27 — — WO disclosed
EP-0839829-A2 Universal solid support oligonucleotide reagents BECKMAN INSTRUMENTS, INC. (US) 1998-05-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11485753-B2 Substituted nucleosides, nucleotides and analogs thereof PNP, NUDT1, NT5C2 CA9 4699/4885CA12 4861/4885CA1 4884/4885
US-20090176732-A1 PROTECTED NUCLEOTIDE ANALOGS NTPCR, NT5C2, PNP CA9 3651/4885CA12 4751/4885CA1 4729/4885
US-11590155-B2 Substituted nucleosides, nucleotides and analogs thereof PNP, NUDT1, NT5C3B CA9 4577/4885CA12 4811/4885CA1 4869/4885
US-20080207554-A1 2-5A Analogs and their Methods of Use RNASEL, RNASE1, RNASEH1 CA9 3576/4885CA12 4279/4885CA1 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.